Cofoe Medical Successfully Lists on Hong Kong Stock Exchange, Achieving Dual Listing in Mainland China and Hong Kong

Publish Time: 2026-05-06     Origin: Site

We are beyond excited to announce that on May 6, 2026 - Cofoe Medical Technology Co., Ltd. officially went public on the Main Board of the HongKong Stock Exchange (stock code: 01187.HK)!

✨Already listed in Mainland China (SZSE: 301087) since 2021, we have now achieved a dual listing in both Mainland China and Hong Kong - a MASSIVE leap toward our global future!

After nearly 20 years of dedication to home medical devices, we are now ready to serve the word from a stronger, international capital platform.

And we're starting strong: Q1 2026 results

▪️ Revenue: RMB 1.012 billion (+37% vs. last year)

▪️ Recurring Net Profit: RMB 94 million (+37% vs. last year)

2025 was already a record year: RMB 3.387B revenue, #1 market share in rehabilitation aids in China, and overseas revenue growth of over 400%!

Innovation that makes a difference

We are now an R&D powerhouse – creating smarter, warmer, more accessible medical technologies:

World's first one-drop blood test for both glucose & uric acid

Cofoe AI Research Institute + in-house LLM (Large Language Model) coming soon

C11 smart ventilator – as quiet as 23dB for better sleep

AI bone-conduction hearing aids (with Tencent Tianlai) – world-class clarity at 1/5 the cost of imports

Going global, fast

▪️ Acquired Shanghai Huazhou & Hong Kong Humana → filled our channel map in Europe, US, and Southeast Asia.

▪️ Partnered with Royal Philips → exclusive rights to 7 core categories in Greater China. A true fusion of global brand and smart Chinese manufacturing.

This is the beginning. The best is yet to come!!!

Sign up for our Latest newsletter
Copyright © 2012- 2022 Cofoe Medical Technology Co., Ltd.   Sitemap/Support By Leadong